NCT04334564 is a NA clinical trial of Ginkgo biloba capsule in Primary Open Angle Glaucoma, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University.

Who is sponsoring NCT04334564?

NCT04334564 is sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University.

What drugs are being tested in NCT04334564?

Interventions in NCT04334564: Ginkgo biloba capsule, Placebos.

What condition does NCT04334564 study?

NCT04334564 studies Primary Open Angle Glaucoma, Drug Effect.

Is NCT04334564 still recruiting?

NCT04334564 is currently status unknown. Last updated 6 April 2020.

Last reviewed 2020-04-06 · How we verify

NCT04334564

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Ginkgo Biloba Capsule on Visual Function of Primary Open-angle Glaucoma With Blood Stasis Syndrome

Status unknown NA Last updated 6 April 2020

What this trial tests

NA trial testing Ginkgo biloba capsule in Primary Open Angle Glaucoma in 512 participants. Status unknown.

Timeline

28 April 2015

Primary endpoint
30 October 2020

30 November 2020

Quick facts

Lead sponsor	Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	512
Start date	28 April 2015
Primary completion	30 October 2020
Estimated completion	30 November 2020
Sites	1 location across China

Drugs / interventions tested

Ginkgo biloba capsule
Placebos — full drug profile →

Conditions studied

Primary Open Angle Glaucoma — all drugs for Primary Open Angle Glaucoma →
Drug Effect — all drugs for Drug Effect →

Sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University

Who can join

Adults 30 to 65, any sex, with Primary Open Angle Glaucoma or Drug Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Open Angle Glaucoma (POAG) is an eye disease that causes optic nerve damage, visual field defect, and blindness caused by increased intraocular pressure. In recent years, many studies have shown that ginkgo biloba extract has a protective effect on the visual function of glaucoma patients. Studies have shown that Ginkgo biloba capsules can improve the visual field damage of glaucoma controlled by intraocular pressure;Ginkgo biloba capsule can promote the recovery of visual evoked potential of glaucoma controlled by intraocular pressure; the improvement of visual field has a certain correlation with visual electrophysiological recovery. The mechanism may be achieved by suppressing the influx of calcium ions and thereby inhibiting the apoptosis of cells. Therefore, in this clinical study, effect of Ginkgo biloba capsule on visual function of primary open-angle glaucoma with blood stasis syndrome was evaluated by placebo as control.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Primary Open Angle Glaucoma

Currently open trials in the same condition.

NCT07390890 — DSLT for Reducing Medication in Glaucoma · recruiting
NCT07447011 — Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea · NA · recruiting
NCT07358650 — Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients W · NA · recruiting
NCT06948773 — A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) · NA · recruiting
NCT05439161 — XEN Glaucoma Gel Stent Versus Trabeculectomy · NA · recruiting

Other Zhongshan Ophthalmic Center, Sun Yat-sen University trials

Trials by the same sponsor.

NCT07524725 — Effect of Behavioral Intervention (Baduanjin Alone or Laughter Exercise Plus Artificial Tears) Versus Artificial Tear on · NA · not yet recruiting
NCT07096622 — Efficacy of Visual and Perceptual Training on Visual Function for Operative Congenital Ectopia Lentis Children · NA · not yet recruiting
NCT06098677 — Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects · NA · not yet recruiting
NCT07512115 — The Impact of 'A Miss Is as Good as a Mile': Is Compensation Necessary for Minimal Ocular Deviation in Myopic Laser Surg · NA · not yet recruiting
NCT07512089 — Comparison of PRESBYOND Laser Blended Vision and Conventional Monovision LASIK in Individuals With Presbyopia: A Randomi · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04334564 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongshan Ophthalmic Center, Sun Yat-sen University
Last refreshed: 6 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04334564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing